<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:media="http://search.yahoo.com/mrss/" version="2.0">
<channel>
<title><![CDATA[RSS for Vertex Pharmaceuticals]]></title>
<description><![CDATA[Watch breaking news videos and read news updates about Vertex Pharmaceuticals on FOXBusiness.com.]]></description>
<link><![CDATA[http://www.foxbusiness.com/search-results/]]></link>
<atom:link xmlns:atom="http://www.w3.org/2005/Atom" type="application/rss+xml" rel="self" href="http://www.foxbusiness.com/search-results/urss?pageid=182103"/>
<item>
<title><![CDATA[Vertex Pharmaceuticals Swings to 1st-Quarter Loss on Write-Down]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/30/vertex-pharmaceuticals-swings-to-1st-quarter-loss-on-write-down/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/30/vertex-pharmaceuticals-swings-to-1st-quarter-loss-on-write-down/</guid>
<pubDate><![CDATA[Tue, 30 Apr 2013 18:58:50 EDT]]></pubDate>
<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) swung to a first-quarter loss as sales of its hepatitis C drug plummeted from a year earlier and the company wrote down the value of one of its pipeline drugs.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[FDA Gives 'Breakthrough' Designation to Merck Skin-Cancer Drug]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/23/fda-gives-breakthrough-designation-to-merck-skin-cancer-drug/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/23/fda-gives-breakthrough-designation-to-merck-skin-cancer-drug/</guid>
<pubDate><![CDATA[Wed, 24 Apr 2013 10:10:52 EDT]]></pubDate>
<description><![CDATA[An experimental Merck & Co.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Market Wrap for Friday, April 19: S&P 500 and Nasdaq Composite Jump; Dow Lags After IBM Earnings]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/19/market-wrap-for-friday-april-1-sp-500-and-nasdaq-composite-jump-dow-lags-after/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/19/market-wrap-for-friday-april-1-sp-500-and-nasdaq-composite-jump-dow-lags-after/</guid>
<pubDate><![CDATA[Fri, 19 Apr 2013 12:30:30 EDT]]></pubDate>
<description><![CDATA[The U.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Vertex News Lifts Biotech ETFs]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/19/vertex-news-lifts-biotech-etfs/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/19/vertex-news-lifts-biotech-etfs/</guid>
<pubDate><![CDATA[Fri, 19 Apr 2013 06:52:13 EDT]]></pubDate>
<description><![CDATA[Shares of biotechnology firm Vertex Pharmaceuticals (NASDAQ:VRTX) are soaring by more than 55 percent early Friday and have touched a new all-time high after the company announced late Thursday that its cystic fibrosis drug Kalydeco and an experimental treatment, VX-661, showed promising results in a mid-stage clinical trial.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Vertex Pharmaceuticals Shares Surge on Cystic Fibrosis Data]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/18/vertex-pharmaceuticals-shares-surge-on-cystic-fibrosis-data/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/18/vertex-pharmaceuticals-shares-surge-on-cystic-fibrosis-data/</guid>
<pubDate><![CDATA[Thu, 18 Apr 2013 19:35:36 EDT]]></pubDate>
<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) said data from a mid-stage trial showed significant improvements in lung function among adults with the most common type of the cystic fibrosis, validating the company's research strategy on the disease.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Vertex Signs Deal With Bristol-Myers for Hepatitis C Treatment Studies]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/05/vertex-signs-deal-with-bristol-myers-for-hepatitis-c-treatment-studies/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/05/vertex-signs-deal-with-bristol-myers-for-hepatitis-c-treatment-studies/</guid>
<pubDate><![CDATA[Fri, 05 Apr 2013 08:43:44 EDT]]></pubDate>
<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) entered a nonexclusive agreement with Bristol-Myers Squibb Co.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Moving Averages Indicate These Sector ETFs Could be Stretched]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/03/25/moving-averages-indicate-these-sector-etfs-could-be-stretched/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/03/25/moving-averages-indicate-these-sector-etfs-could-be-stretched/</guid>
<pubDate><![CDATA[Mon, 25 Mar 2013 13:36:13 EDT]]></pubDate>
<description><![CDATA[In a previous examination of some ETFs and their relationship to simple moving averages, we looked at a group of funds that were either below or vulnerable to giving up their 50-day moving averages.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Rise of Generics, Specialty Drugs Prompt Shift in Drug Spending]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/03/05/rise-generics-specialty-drugs-prompt-shift-in-drug-spending/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/03/05/rise-generics-specialty-drugs-prompt-shift-in-drug-spending/</guid>
<pubDate><![CDATA[Tue, 05 Mar 2013 00:16:31 EST]]></pubDate>
<description><![CDATA[U.S. spending on basic prescription drugs like cholesterol-lowering pills recorded a rare decline last year under pressure from generics, but spending on more complicated drugs continued to soar, raising challenges for health-care payers, according to the nation's biggest pharmacy-benefit manager.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/12/28/short-interest-swings-in-biotech-stocks-celg-gild-regn/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/12/28/short-interest-swings-in-biotech-stocks-celg-gild-regn/</guid>
<pubDate><![CDATA[Fri, 28 Dec 2012 07:10:13 EST]]></pubDate>
<description><![CDATA[The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of December.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Vertex's Hepatitis C Drug Receives Another Blow With FDA Warning]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/12/19/vertex-hepatitis-c-drug-receives-another-blow-with-fda-warning/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/12/19/vertex-hepatitis-c-drug-receives-another-blow-with-fda-warning/</guid>
<pubDate><![CDATA[Wed, 19 Dec 2012 16:54:15 EST]]></pubDate>
<description><![CDATA[The Food and Drug Administration on Wednesday placed a new label on Vertex Pharmaceuticals Inc.'s (VRTX) hepatitis C drug Incivek, warning patients that the drug has caused fatal skin rashes in some patients.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/12/12/short-interest-swings-in-biotech-stocks-biib-celg-vvus/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/12/12/short-interest-swings-in-biotech-stocks-biib-celg-vvus/</guid>
<pubDate><![CDATA[Wed, 12 Dec 2012 10:01:06 EST]]></pubDate>
<description><![CDATA[The short interest in biotech and emerging pharmaceutical companies was mixed again in the final two weeks of November.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Vertex Shares Fall as Worries Over Growth Prospects Rise]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/11/02/vertex-shares-fall-as-worries-over-growth-prospects-rise/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/11/02/vertex-shares-fall-as-worries-over-growth-prospects-rise/</guid>
<pubDate><![CDATA[Fri, 02 Nov 2012 14:15:43 EDT]]></pubDate>
<description><![CDATA[Vertex Pharmaceuticals Inc's (VRTX) shares fell as much as 17% Friday after disappointing third-quarter sales of its hepatitis C and cystic fibrosis treatments raised concerns about the company's growth prospects in those key markets.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Factbox: U.S. companies delay results due to Sandy]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/10/30/factbox-us-companies-delay-results-due-to-sandy742096/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/10/30/factbox-us-companies-delay-results-due-to-sandy742096/</guid>
<pubDate><![CDATA[Tue, 30 Oct 2012 12:01:59 EDT]]></pubDate>
<description><![CDATA[Dozens of U.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Sandy Delays Quarterly Results]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/10/30/refile-factbox-us-companies-delay-results-due-to-sandy304455/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/10/30/refile-factbox-us-companies-delay-results-due-to-sandy304455/</guid>
<pubDate><![CDATA[Tue, 30 Oct 2012 08:10:20 EDT]]></pubDate>
<description><![CDATA[Dozens of U.S. companies postponed releasing quarterly results after Sandy flooded large parts of New York City.  Here's a list of companies announcing delayed results and/or conference calls.]]></description>
<media:thumbnail>http://global.fncstatic.com/static/managed/img/fb2/video/103112_fb_bianco.jpg</media:thumbnail>
</item>
<item>
<title><![CDATA[Companies Postpone Earnings Reports in Light of Hurricane Sandy]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/10/29/companies-postpone-earnings-reports-in-light-hurricane-sandy/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/10/29/companies-postpone-earnings-reports-in-light-hurricane-sandy/</guid>
<pubDate><![CDATA[Mon, 29 Oct 2012 15:52:58 EDT]]></pubDate>
<description><![CDATA[A number of U.S. companies disclosed plans to postpone their quarterly reports because of the pending arrival of Hurricane Sandy on the East Coast, a move that comes during one of the busiest weeks of the third-quarter earnings season.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Factbox: Companies delay results due to hurricane]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/10/29/factbox-companies-delay-results-due-to-hurricane/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/10/29/factbox-companies-delay-results-due-to-hurricane/</guid>
<pubDate><![CDATA[Mon, 29 Oct 2012 14:10:36 EDT]]></pubDate>
<description><![CDATA[Dozens of U.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/10/25/short-interest-swings-in-biotech-stocks-biib-gild-vvus/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/10/25/short-interest-swings-in-biotech-stocks-biib-gild-vvus/</guid>
<pubDate><![CDATA[Thu, 25 Oct 2012 10:09:59 EDT]]></pubDate>
<description><![CDATA[The short interest in biotech and emerging pharmaceutical companies was mixed in the first two weeks of October.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[J&J profit beats as newer drugs, devices deliver]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/10/16/jj-profit-beats-as-newer-drugs-devices-deliver/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/10/16/jj-profit-beats-as-newer-drugs-devices-deliver/</guid>
<pubDate><![CDATA[Tue, 16 Oct 2012 13:46:05 EDT]]></pubDate>
<description><![CDATA[Healthcare giant Johnson & Johnson reported better-than-expected third-quarter results on Tuesday, as newer drugs, including a treatment for prostate cancer, led a rebound in sales and investor jitters about medical device sales proved unfounded.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Abbott Hepatitis C Regimen Suppresses Virus in New Study]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/10/15/abbott-hepatitis-c-regimen-suppresses-virus-in-new-study/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/10/15/abbott-hepatitis-c-regimen-suppresses-virus-in-new-study/</guid>
<pubDate><![CDATA[Mon, 15 Oct 2012 13:56:42 EDT]]></pubDate>
<description><![CDATA[An experimental all-oral drug regimen developed by Abbott Laboratories (ABT) suppressed the hepatitis C virus in most patients in a new clinical trial.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Short Interest Swings in Biotech Stocks (BIIB, CELG, GILD)]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/10/15/short-interest-swings-in-biotech-stocks-biib-celg-gild/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/10/15/short-interest-swings-in-biotech-stocks-biib-celg-gild/</guid>
<pubDate><![CDATA[Mon, 15 Oct 2012 02:59:08 EDT]]></pubDate>
<description><![CDATA[After largely rising in the previous period, short interest in biotech and emerging pharmaceutical companies was mixed in the final two weeks of September.]]></description>
<media:thumbnail/>
</item>
</channel>
</rss>
